Latest Ratios: P/E Ratio -1.5x · EV/EBITDA N/A · ROE -54.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $113M | $108M | $129M | $26M | $14M | $76M | $98M | $349M | $333M | $356M | $348M |
| Enterprise Value | $86M | $82M | $115M | $33M | $22M | $77M | $39M | $327M | $292M | $294M | $333M |
| P/E Ratio → | -1.53 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 85.93 | 24.81 | 9.65 | 69.03 | 146.00 | 181.86 |
| P/B Ratio | 0.81 | 0.73 | 0.90 | — | 0.42 | 1.10 | 2.16 | 56.66 | 12.09 | 6.17 | 38.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 87.72 | 9.92 | 9.04 | 60.45 | 120.50 | 174.16 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | -85.9% | 100.0% | -147.9% | -908.1% | -967.1% | -707.6% |
| Operating Margin | — | — | — | — | — | -6350.1% | -3119.2% | -213.3% | -1176.8% | -1334.4% | -1045.6% |
| Net Profit Margin | — | — | — | — | — | -5166.4% | -2826.1% | -197.7% | -1154.5% | -1328.6% | -1046.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.2% | -54.2% | -59.3% | -342.0% | -109.4% | -79.6% | -432.7% | -424.3% | -130.5% | -97.2% | -223.4% |
| ROA | -48.5% | -48.5% | -43.7% | -94.3% | -64.2% | -43.4% | -147.0% | -148.7% | -97.7% | -76.4% | -130.0% |
| ROIC | -51.4% | -51.4% | -56.8% | -163.6% | -46.8% | -146.4% | — | — | — | — | — |
| ROCE | -58.5% | -58.5% | -69.4% | -180.1% | -48.3% | -69.5% | -290.2% | -357.3% | -129.5% | -96.1% | -219.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | — | 0.76 | 0.38 | 0.59 | 1.53 | 0.01 | 0.01 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.18 | -0.10 | — | 0.25 | 0.02 | -1.29 | -3.62 | -1.50 | -1.08 | -1.65 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -20.48 | -13.94 | -18.86 | -30.59 | -119.42 | — | — | — | — |
Net cash position: cash ($28M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.07 | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 | 2.89 | 1.09 | 2.45 | 7.98 | 1.96 |
| Quick Ratio | 8.07 | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 | 2.88 | 1.17 | 2.45 | 7.98 | 1.96 |
| Cash Ratio | 7.89 | 7.89 | 12.61 | 0.66 | 4.68 | 5.74 | 2.68 | 0.91 | 2.31 | 7.62 | 1.68 |
| Asset Turnover | — | — | — | — | — | 0.01 | 0.04 | 0.74 | 0.10 | 0.04 | 0.11 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 999999.00 |
| Days Sales Outstanding | — | — | — | — | — | — | 239.02 | 27.07 | — | — | 254.05 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $13M | $11M | $4M | $4M | $4M | $3M | $2M | $2M | $2M | $1M |
Clinical trial funding exhaustion
According to recent market data, Corbus trades at a price-to-book ratio of 0.79, which suggests that investors are heavily discounting the company's intangible pipeline assets relative to its historical valuation and the broader peer group of clinical-stage biotechnology firms focused on metabolic and oncology indications.
The current valuation appears to reflect a market skepticism regarding the company's ability to successfully transition its pipeline assets into commercial-stage products. Investors should monitor whether this discount persists as clinical data readouts for CRB-913 and CRB-701 approach, as the current multiple implies a high probability of further equity dilution to sustain operations.
Based on reported financial statements, Corbus has consistently generated negative ROIC, with figures reaching -16.4% in 2026Q1, a trend that highlights the structural inability of a pre-revenue entity to compound capital while simultaneously funding high-cost clinical trials for its emerging metabolic and oncology pipeline.
The persistent decay in return on invested capital is a direct consequence of the company's strategic pivot and the associated heavy R&D expenditure. This negative trend warrants further investigation into whether the current capital allocation toward the Jenrin library and Nectin-4 ADC programs will eventually yield a positive return, or if the current burn rate will continue to erode shareholder value.
As reported in recent SEC filings, the company's current ratio has declined from 12.94 in 2024Q4 to 7.92 in 2026Q1, indicating that while the firm maintains a superficial liquidity cushion, the rapid consumption of cash to fund clinical execution is steadily narrowing its operational runway.
The decline in the current ratio suggests that the company's ability to withstand severe operational stress is diminishing as cash reserves are depleted. Investors should monitor the company's cash-to-burn ratio closely, as the current liquidity position may necessitate a dilutive financing event well before the next major clinical milestone is reached.
The most commonly misapplied metric for Corbus is the P/E ratio, which, at -1.48 TTM, obscures the company's true economic potential by focusing on accounting losses rather than the underlying value of its clinical-stage assets and the potential for future milestone-based revenue or strategic acquisition.
Using P/E to evaluate a pre-revenue biotech firm is fundamentally flawed because it ignores the R&D-driven nature of the business model where losses are a deliberate investment in future intellectual property. Analysts should instead focus on cash runway, probability-adjusted net present value of the pipeline, and the scarcity value of the Nectin-4 ADC asset relative to industry peers.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRBP stock.
Corbus Pharmaceuticals Holdings, Inc.'s current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
Corbus Pharmaceuticals Holdings, Inc.'s return on equity (ROE) is -54.2%. The historical average is -183.0%.
Based on historical data, Corbus Pharmaceuticals Holdings, Inc. is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.